Nephrotic syndrome with focal segmental glomerulosclerosis induced by intravitreal injections of vascular endothelial growth factor inhibitor

Kota Kakeshita, Tsutomu Koike, Teruhiko Imamura*, Sayaka Murai, Hayato Fujioka, Hidenori Yamazaki, Koichiro Kinugawa

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

An 83-year-old woman with a 1-year history of scheduled intravitreal injection of vascular endothelial growth factor (VEGF) inhibitor (aflibercept) was diagnosed with nephrotic syndrome due to focal segmental glomerulosclerosis with histopathological findings of segmental infiltration of foam cells in the glomerular capillaries. Her nephrotic syndrome improved immediately following the termination of aflibercept intravitreal injection without steroid therapy. Although widely used to treat ophthalmic diseases, we should keep in mind that even intravitreal injection of VEGF inhibitor, as opposed to systemic administration, can cause kidney injury.

Original languageEnglish
Pages (from-to)3051-3054
Number of pages4
JournalInternal Medicine
Volume59
Issue number23
DOIs
StatePublished - 2020/12/01

Keywords

  • Aflibercept
  • Podocyte
  • Proteinuria
  • VEGF inhibitor

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Nephrotic syndrome with focal segmental glomerulosclerosis induced by intravitreal injections of vascular endothelial growth factor inhibitor'. Together they form a unique fingerprint.

Cite this